The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
EHA2023 abstracts: What’s hot in MPN?
To help navigate the exciting content being presented at the EHA2023 Congress, the MPN Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MPN.
Friday, June 9, 2023
Saturday, June 10, 2023
|
Abstract |
Type |
Title |
Presenter |
|
S210 |
Oral presentation |
An open-label, global, phase 1b/2 study adding navtemadlin (NVTM) to ruxolitinib (RUX) in patients with primary or secondary myelofibrosis who have a suboptimal response to RUX |
John Mascarenhas |
|
S211 |
Oral presentation |
Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-1 risk myelofibrosis: Updated results and genomic characteristics |
Harry Gill |
|
S212 |
Oral presentation |
A randomized double-blind phase 3 study of jaktinib versus hydroxyurea in patients with intermediate-2 or high risk myelofibrosis |
Yi Zhang |
|
S213 |
Oral presentation |
BMS-986158, a potent BET inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis: Results from a phase 1/2 study |
Haifa Kathrin |
Sunday, June 11, 2023
|
Abstract |
Type |
Title |
Presenter |
|
LB2710 |
Late breaking oral presentation |
Marina Kremyanskaya |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content